Previous 10 | Next 10 |
The shares of commercial-stage biotech Palatin Technologies, Inc. ( NYSE: PTN ) jumped ~24% Thursday on above-average volume after the company announced the initiation of its Phase 2 clinical study for PL8177, an oral candidate for ulcerative colitis. The trial with a ...
Palatin Announces Initiation of Patient Recruitment for Phase 2 Clinical Study Evaluating Oral PL8177 for Treatment of Ulcerative Colitis PR Newswire Study Designed to Evaluate the Safety, Tolerability, and Efficacy with PL8177 Oral Colon Delivery in Adult Subjects wit...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips How do you find the best penny stocks? The answer may seem simple, but it’s not. Many things can affect your decision and make finding a good buy tough for even the most experienced investors. One thing to look out...
Palatin Technologies Inc. (NYSE American:PTN) traded at a new 52-week high today of $4.93. So far today approximately 137,000 shares have been exchanged, as compared to an average 30-day volume of 1.3 million shares. In the past 52 weeks, Palatin Technologies Inc. share prices are bracke...
Commercial-stage biotech Palatin Technologies ( NYSE: PTN ) lost ~13% in pre-market trading Friday after the company announced its plans to implement a 1-for-25 reverse split of its common stock. The reverse stock split is expected to take effect at 5:00 p.m. on Aug. 3...
Palatin Announces Intent to Effect Reverse Stock Split PR Newswire Common Stock Will Begin Trading on a Split-Adjusted Basis on August 31, 2022 CRANBURY, N.J. , Aug. 19, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharma...
Palatin Technologies ( NYSE: PTN ) said a data monitoring committee (DMC) recommended to continue a phase 3 trial of PL9643 to treat patients with dry eye disease (DED) after review of an interim analysis of the study was completed. The interim analysis inclu...
Palatin Reports Positive Interim Analysis in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease PR Newswire Independent Data Monitoring Committee Recommends Continuing Study with Sample Size Target of up to 350 Patients – up to Additional 230 Pat...
Palatin Technologies ( NYSE: PTN ) shares gained ~8% pre-market on Tuesday after the biopharmaceutical company reported prelim Q4 sales for its Vyleesi product. Vyleesi, said to be the first and only as-needed treatment approved by the FDA for premenopausal women with ...
Palatin Announces Preliminary Fourth Quarter Vyleesi® Net Product Revenue Increased 225% Over Prior Quarter PR Newswire Gross product sales increased 75% and Prescriptions dispensed increased 45%, over prior quarter CRANBURY, N.J. , July 26...
News, Short Squeeze, Breakout and More Instantly...
Palatin Technologies Inc. Company Name:
PTN Stock Symbol:
NYSE Market:
Palatin Technologies Inc. Website:
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity PR Newswire Phase 2 clinical study expected to begin in mid-calendar year 2024 Topline data expected by calendar ye...
Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024 PR Newswire CRANBURY, N.J. , April 30, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (N...
The Dow Jones index closed slightly lower on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the c...